Pfizer's decision late on Wednesday to withdraw its sickle cell disease treatment due to the risk of death could help speed ...

The U.S. Food and Drug Administration on Thursday alerted patients and healthcare professionals about the withdrawal of ...

Pfizer Inc. (NYSE:PFE) said the company is voluntarily withdrawing all lots of Oxbryta (voxelotor) for the treatment of ...

PFE's decision is based on clinical data, which suggests that the overall benefit of the drug no longer outweighs the risk in ...

Based on new safety signals, Pfizer on Wednesday announced that Oxbryta’s overall benefit “no longer outweighs the risk” in ...

The company said benefits no longer outweighed the risks, with data suggesting the drug might increase the risk of pain ...

Pfizer is withdrawing all of its sickle cell disease drug, Oxbryta, worldwide because of safety concerns. Pfizer ( PFE) ...

Pfizer has withdrawn Oxbryta from global markets and halted all clinical trials, citing safety concerns following clinical data that raised issues about fatal complications in sickle cell disease ...

The EU's drug watchdog Thursday called for the suspension of approval for Pfizer's medicine to treat sickle cell disease, ...

Pfizer (PFE – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Mohit Bansal ...

Pfizer has withdrawn Oxbryta (voxelotor), a sickle cell disease treatment, from global markets due to new clinical data ...

The US big pharma company Pfizer has voluntarily withdrawn the oral sickle cell disease treatment Oxbryta from the market and ...